Severe acute respiratory syndrome coronavirus 2 Delta variant replication (SARS-CoV-2 Delta replication)

Severe acute respiratory syndrome coronavirus 2 Delta variant replication is the multi-step biological process by which the B.1.617.2 lineage of the virus reproduces within host cells [V'kovski et al., Nature Reviews Microbiology, 2021]. This cycle begins with the Spike protein-mediated entry into host cells, which is significantly enhanced in the Delta variant by the P681R mutation that optimizes furin cleavage [Liu et al., Nature, 2021]. Once the viral RNA is released into the cytoplasm, it is translated into large polyproteins that are subsequently cleaved into functional non-structural proteins by the viral Main Protease (Mpro) and Papain-like Protease (PLpro) [Jin et al., Nature, 2020]. The replication of the viral genome is then managed by the replicase-transcriptase complex, centered around the RNA-dependent RNA polymerase (RdRp) [Hillen et al., Science, 2020]. Therapeutic strategies targeting Delta variant replication focus on these highly conserved enzymatic components to arrest viral proliferation and mitigate COVID-19 severity. Small-molecule inhibitors such as Nirmatrelvir target Mpro to prevent polyprotein processing, while Remdesivir and Molnupiravir target the RdRp to induce chain termination or lethal mutagenesis [Lamb, Drugs, 2022; Jayk Bernal et al., NEJM, 2022]. Despite the high replication fitness of the Delta variant, these enzymatic targets remain relatively stable compared to the rapidly mutating Spike protein [Vangeel et al., Antiviral Research, 2022]. However, clinical challenges include the potential for resistance mutations and significant drug-drug interactions, particularly with Ritonavir-boosted regimens [Helsby et al., British Journal of Clinical Pharmacology, 2022].

Other names

B.1.617.2 replicationSARS-CoV-2 Delta variant viral cycleDelta variant RNA synthesisSARS-CoV-2 Delta variant life cycle

Inhibition of viral RNA-dependent RNA polymerase (RdRp) or viral main protease (Mpro/3CLpro) to prevent the synthesis of viral RNA and functional proteins.